A Study to Test the Pharmacokinetics, Efficacy, and Safety of Brivaracetam in Newborns With Repeated Electroencephalographic Seizures
- Conditions
- Interventions
- First Posted Date
- 2017-10-30
- Last Posted Date
- 2024-04-08
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 9
- Registration Number
- NCT03325439
- Locations
- 🇨🇿
N01349 205, Praha, Czechia
🇧🇪N01349 204, Leuven, Belgium
🇫🇷N01349 207, Lille, France
A Study to Test the Safety/ Efficacy of Brivaracetam (BRV) Used as Adjunctive Treatment in Subjects >=16 Years of Age With Partial Seizures With or Without Secondary Generalization
- Conditions
- Interventions
- First Posted Date
- 2017-08-15
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 217
- Registration Number
- NCT03250377
- Locations
- 🇨🇳
Ep0085 905, Beijing, China
🇨🇳Ep0085 901, Chengdu, China
🇨🇳Ep0085 902, Guangzhou, China
A Study to Test the Efficacy, Safety and Pharmacokinetics of Bimekizumab in Subjects With Moderate to Severe Hidradenitis Suppurativa.
- Conditions
- Interventions
- First Posted Date
- 2017-08-14
- Last Posted Date
- 2022-04-11
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 90
- Registration Number
- NCT03248531
- Locations
- 🇺🇸
Hs0001 115, Las Vegas, Nevada, United States
🇧🇪Hs0001 203, Brussels, Belgium
🇳🇴Hs0001 701, Harstad, Norway
A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Adult Patients With Chronic Plaque Psoriasis
- First Posted Date
- 2017-07-26
- Last Posted Date
- 2022-07-22
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 43
- Registration Number
- NCT03230292
- Locations
- 🇦🇺
Ps0018 101, Carlton, Australia
🇨🇦Ps0018 201, Ajax, Canada
🇦🇺Ps0018 103, East Melbourne, Australia
A Study to Test the Efficacy and Safety of Bimekizumab and Certolizumab Pegol in Patients With Active Ankylosing Spondylitis
- Conditions
- Interventions
- First Posted Date
- 2017-07-12
- Last Posted Date
- 2023-07-27
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 76
- Registration Number
- NCT03215277
- Locations
- 🇬🇷
As0013 406, Thessaloníki, Greece
🇵🇱As0013 708, Białystok, Poland
🇵🇱As0013 709, Kraków, Poland
A Study to Evaluate the Efficacy and Safety of Brivaracetam in Study Participants (>=16 to 80 Years of Age) With Epilepsy
- Conditions
- Interventions
- First Posted Date
- 2017-03-20
- Last Posted Date
- 2024-06-11
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 449
- Registration Number
- NCT03083665
- Locations
- 🇨🇳
Ep0083 902, Guangzhou, China
🇨🇳Ep0083 912, Hangzhou, China
🇨🇳Ep0083 910, Shijiazhuang, China
A Study to Evaluate the Pharmacokinetics (PK), Pharmacodynamics (PD), and Safety of Bimekizumab in Patients With Chronic Plaque Psoriasis
- First Posted Date
- 2017-01-19
- Last Posted Date
- 2022-10-28
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 49
- Registration Number
- NCT03025542
- Locations
- 🇦🇺
Ps0016 102, Kogarah, Australia
🇺🇸Ps0016 704, Bexley, Ohio, United States
🇦🇺Ps0016 101, Melbourne, Australia
A Study to Assess the Effects of Certolizumab Pegol on the Reduction of Anterior Uveitis (AU) Flares in Axial Spondyloarthritis Subjects With a Documented History of AU
- Conditions
- Interventions
- First Posted Date
- 2017-01-13
- Last Posted Date
- 2021-02-09
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 89
- Registration Number
- NCT03020992
- Locations
- 🇵🇱
As0007 509, Poznań, Poland
🇨🇿As0007 103, Brno, Czechia
🇩🇪As0007 302, München, Germany
A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Patients With Chronic Plaque Psoriasis
- First Posted Date
- 2017-01-05
- Last Posted Date
- 2022-10-18
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 217
- Registration Number
- NCT03010527
- Locations
- 🇺🇸
Ps0011 709, Houston, Texas, United States
🇺🇸Ps0011 733, Dallas, Texas, United States
🇵🇱Ps0011 608, Krakow, Poland
Study to Evaluate Safety, Tolerability and Efficacy of UCB7665 in Subjects With Primary Immune Thrombocytopenia
- First Posted Date
- 2016-03-24
- Last Posted Date
- 2024-01-29
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 66
- Registration Number
- NCT02718716
- Locations
- 🇲🇩
Tp0001 601, Chisinau, Moldova, Republic of
🇧🇬Tp0001 1301, Sofia, Bulgaria
🇵🇱Tp0001 703, Gdańsk, Poland